ALL-REMOTE COMPANY/WILMINGTON, Del. / Sep 30, 2025 / Business Wire / Phreesia, a leader in patient intake, outreach and activation, has been named to TIME’s list of the World’s Top HealthTech Companies of 2025. The list, developed in partnership with Statista, highlights health tech companies that drive innovation, enhance accessibility, and contribute to a more effective and sustainable healthcare ecosystem.
“Digital health’s primary benefit will be in empowering patients to both learn more about their health, and also to take action to either avoid or manage conditions better,” TIME said in its announcement of the inaugural list.
Organizations were ranked based on financial performance, reputation analysis and online engagement, and categorized into six different market segments. Phreesia received a ‘very high’ performance indicator in the Health Information & Management category.
“We are honored to be named one of TIME’s top health tech companies,” said Phreesia CEO Chaim Indig. “Phreesia’s vision is for every person to take an active role in their care, and we believe our digital solutions help patients and providers do just that. Facilitating 170 million patient visits annually gives us the scale to make a meaningful impact.”
For more information on Phreesia, visit www.phreesia.com.
About Phreesia
Phreesia is the trusted leader in patient activation, giving healthcare providers, life sciences companies and other organizations tools to help patients take a more active role in their care. Founded in 2005, Phreesia enabled approximately 170 million patient visits in 2024—1 in 7 visits across the U.S.—scale that we believe allows us to make meaningful impact. Offering patient-driven digital solutions for intake, outreach, education and more, Phreesia enhances the patient experience, drives efficiency and improves healthcare outcomes. To learn more, visit www.phreesia.com.
| Last Trade: | US$16.25 |
| Daily Change: | 0.21 1.31 |
| Daily Volume: | 2,060,188 |
| Market Cap: | US$973.540M |
December 08, 2025 September 04, 2025 September 04, 2025 September 02, 2025 May 28, 2025 | |

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load